Clinical Trial Update: Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation. [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 trial evaluates alpelisib for lymphatic malformations associated with PIK3CA mutations in pediatric and adult patients; recruitment is ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphatic Malformation

Drugs mentioned

• Piqray (alpelisib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Lymphatic Malformations | Phase 2, Phase 3 | Status: RECRUITING